# December 2021 Quarterly Update and Appendix 4C

## HIGHLIGHTS:

- **Strong cash position of $14.77 million to support multiple cancer therapy programs**
- **Unique pre-clinical data confirming next-generation potential of OmniCAR**
- **Two more highly-respected international medical and scientific experts join SAB**
- **Post reporting period: PTX receives accreditation from Office of the Gene Regulator for CAR-T clinical trials**

**MELBOURNE Australia, 31 January 2022** – Prescient Therapeutics (ASX: PTX), a clinical-stage oncology company developing personalized therapies for cancer, today reported its December 2021 quarter results and operating highlights.

Prescient continued to meet all clinical and business development milestones and ended the quarter in a strong clinical and financial and position.

The therapeutic potential of Prescient's anti-cancer therapy programs continues to attract interest from leaders in the international medical community.

## Strong financial position

The Company continues to progress development whilst managing finances responsibly. Prescient ended the quarter with a cash balance of $14.77 million. An Australian Government Research and Development tax refund of AU$1.33 million was received in November 2021.

Costs for the quarter included ongoing clinical trials and manufacturing for PTX-100 and PTX-200 as well as development of the OmniCAR next-generation CAR-T platform. Cash outflows for the quarter were $1.45 million (excluding the abovementioned tax refund), with $827,023 invested in research and development activities.

Payments during the quarter to related parties of the entity and their associates were $150,084. These payments related to executive and non-executive director fees, salary and superannuation.

The estimated cash available for future operating activities of 121 quarters is determined using requisite reporting calculations and includes the impact of the R&D refund received during the December 2021 quarter.

Full details are in the attached Appendix 4C for the December 2021 quarter.

## Creating the next-generation of personalised cancer therapies

Cell therapies, such as CAR-T, are the ultimate personalised medicine, able to harness a patient's own immune system to fight cancer.

Prescient is working to transform personalised medicine with next generation cell therapy technologies. OmniCAR has the potential to deliver controllable, flexible CAR-T products that can be directed against a variety of different cancer diseases.

During the quarter, Prescient presented exciting new OmniCAR pre-clinical data at the Cell & Gene Meeting on the Mesa in California, a leading forum for the international medical and investment community focused on new cell therapies.

The new data, some of which Prescient believes to be world-firsts, outlined the key attributes of OmniCAR to generate CAR-T cell therapies that can be controlled post-infusion; re-armed; and re-directed from one cancer antigen to another. Important dose-response cancer killing activity and high potency were demonstrated.

The results showed OmniCAR-T cells begin antigen-directed killing of tumour cells *in vitro* as soon as they are armed. The team also showed that OmniCAR-T cells could be re-armed and continue to kill tumour cells without loss of cytotoxicity, and that OmniCAR can be used to target multiple cancer antigens..

These insights and outcomes are a direct result of Prescient's work in collaboration with the Peter MacCallum Cancer Centre in Melbourne, Australia and have generated interest from a wide range of experts in the international medical and cell therapy community who are beginning to appreciate the capabilities of OmniCAR.

## Working with the world's best

Prescient continues to attract world-leading experts to help guide the Company with unsurpassed insights in a rapidly emerging field. In November, the Company welcomed physician-scientist, Dr Marco

Davila of the Moffitt Cancer Center and bioengineering expert Professor Andrew Tsourkas of the University of Pennsylvania to its multi-disciplinary expert international Scientific Advisory Board (SAB).

Dr Davila and Professor Tsourkas bring deep, complementary expertise to Prescient and join a highly credentialed SAB comprising CAR-T expert Professor Phil Darcy, hematologist and CAR-T researcher Professor Miles H. Prince AM and brain cancer specialist Professor Don O'Rourke.

Dr Davila is a medical oncologist in the Department of Blood and Marrow Transplantation at the Moffitt Cancer Center in the US. His research involves the pre-clinical development and clinical translation of gene-engineered cell therapies and he is regarded as a leading figure in the field.

Professor Tsourkas is a Professor of Bioengineering in the School of Engineering and Applied Sciences at Penn and Co-Director for the Center for Targeted Therapeutic and Translational Nano-medicine. He is a co-inventor of the patents developed at Penn and licensed by Prescient to form OmniCAR. His expertise in the conjugation of proteins is key to the development of OmniCAR's binders, which involves incorporating SpyTag into antibodies and other antigen-binding molecules.

During the quarter, Prescient continued to advance a number of highly promising projects in stealth mode which have the potential to add significant value for the business and clinicians worldwide.

## Developments after the reporting period

After the reporting period, Prescient received accreditation by the Office of the Gene Regulator (OTGR) to enable clinical studies for OmniCAR.

The OTGR accreditation is separate from approval by the Therapeutics Goods Administration. Under the *Gene Technology Act 2000*, the Instrument of Accreditation is a requirement to enable a company to conduct clinical trials in Australia involving gene-edited cells, such as CAR-T therapies.

Prescient Managing Director and CEO Steven Yatomi-Clarke said, "This OGTR accreditation is an important step in the regulatory process to conduct a CAR-T trial in Australia. In addition to our research and development, Prescient is undertaking a significant body of regulatory work as we progress the OmniCAR programs towards clinical trials."

## A positive outlook

Despite the multiple challenges of the pandemic, Prescient continued to execute on its development schedule in a timely manner. The team has demonstrated its ability to work through multiple logistical challenges to ensure our important clinical and pre-clinical work continues and that we meet our commitments to the researchers and patients taking part in our trials.

Prescient begins the new calendar year with great optimism and excitement. The whole team is focused and driven to succeed in the mission to improve cancer treatment by giving doctors cutting edge therapies to help patients with cancer.

Over the coming quarters, Prescient remains focused on taking full advantage of its leadership in the next-generation of targeted cancer treatment to create long-term shareholder value. The Company sincerely thanks all its shareholders and collaborators for their ongoing support of the collective goal of giving medical professionals everywhere more effective new treatments for cancer patients.

-End -

To stay updated with the latest company news and announcements, please update your details on our investor centre.

## About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

### *Cell Therapies*

**OmniCAR:** is a universal immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Prescient is developing OmniCAR programs for next-generation CAR-T therapies for Acute Myeloid Leukemia (AML); Her2+ solid tumours, including breast, ovarian and gastric cancers; and glioblastoma multiforme (GBM).

**Cell Therapy Enhancements:** Prescient has several other initiatives underway to develop new cell therapy approaches.

### *Targeted Therapies*

**PTX-100** is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX- 100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas.

**PTX-200** is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition, PTX-200 has a novel mechanism of action that specifically inhibits Akt without non-specific kinase inhibition effects. This highly promising compound has previously generated encouraging Phase 2a data in HER2-negative breast cancer and Phase 1b in recurrent or persistent platinum resistant ovarian cancer, with a Phase 1b/2 trial currently underway in relapsed and refractory AML.

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

Find out more at www.ptxtherapeutics.com or connect with us via Twitter @PTX_AUS and LinkedIn


Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics
steven@ptxtherapeutics.com

**Investor enquiries:**
Sophie Bradley – Reach Markets
+61 450 423 331
ir@reachmarkets.com.au

**Media enquiries:**
Andrew Geddes – CityPR
+61 2 9267 4511
ageddes@citypublicrelations.com.au

## Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward- looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward- looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

## Supplemental COVID-19 Risk Factors

Please see our website : Supplemental COVID-19 Risk Factors

# Appendix 4C

## Quarterly cash flow report for entities subject to Listing Rule 4.7B



| Name of entity | |
|---|---|
| Prescient Therapeutics Limited | |
| **ABN** | **Quarter ended ("current quarter")** |
| 56 006 569 106 | 31 December 2021 |

| | Consolidated statement of cash flows | Current quarter $A'000 | Year to date (6 months) $A'000 |
|---|---|---|---|
| **1.** | **Cash flows from operating activities** | | |
| 1.1 | Receipts from customers | - | - |
| 1.2 | Payments for | | |
| | (a) research and development | (827) | (1,609) |
| | (b) product manufacturing and operating costs | - | |
| | (c) advertising and marketing | - | - |
| | (d) leased assets | - | - |
| | (e) staff costs | (256) | (472) |
| | (f) administration and corporate costs | (369) | (839) |
| 1.3 | Dividends received (see note 3) | - | - |
| 1.4 | Interest received | 7 | 10 |
| 1.5 | Interest and other costs of finance paid | (4) | (6) |
| 1.6 | Income taxes paid | - | - |
| 1.7 | Government grants and tax incentives | 1,326 | 1,326 |
| 1.8 | Other (provide details if material) | - | - |
| **1.9** | **Net cash from / (used in) operating activities** | **(122)** | **(1,590)** |

| | | | |
|---|---|---|---|
| **2.** | **Cash flows from investing activities** | | |
| 2.1 | Payments to acquire or for: | | |
| | (a) entities | - | - |
| | (b) businesses | - | - |
| | (c) property, plant and equipment | - | - |
| | (d) investments | - | - |
| | (e) intellectual property | - | - |
| | (f) other non-current assets | - | - |

| Consolidated statement of cash flows | | Current quarter $A'000 | Year to date (6 months) $A'000 |
|---|---|---|---|
| 2.2 | Proceeds from disposal of: | | |
| | (a) entities | - | - |
| | (b) businesses | - | - |
| | (c) property, plant and equipment | - | - |
| | (d) investments | - | - |
| | (e) intellectual property | - | - |
| | (f) other non-current assets | - | - |
| 2.3 | Cash flows from loans to other entities | - | - |
| 2.4 | Dividends received (see note 3) | - | - |
| 2.5 | Other (provide details if material) | - | - |
| **2.6** | **Net cash from / (used in) investing activities** | - | - |

| | | | |
|---|---|---|---|
| **3.** | **Cash flows from financing activities** | | |
| 3.1 | Proceeds from issues of equity securities (excluding convertible debt securities) | 94 | 303 |
| 3.2 | Proceeds from issue of convertible debt securities | - | - |
| 3.3 | Proceeds from exercise of options | - | - |
| 3.4 | Transaction costs related to issues of equity securities or convertible debt securities | - | (3) |
| 3.5 | Proceeds from borrowings | - | - |
| 3.6 | Repayment of borrowings | (83) | (83) |
| 3.7 | Transaction costs related to loans and borrowings | - | - |
| 3.8 | Dividends paid | - | - |
| 3.9 | Other (provide details if material) | - | - |
| **3.10** | **Net cash from / (used in) financing activities** | **11** | **218** |

| | | | |
|---|---|---|---|
| **4.** | **Net increase / (decrease) in cash and cash equivalents for the period** | | |
| 4.1 | Cash and cash equivalents at beginning of period | 14,879 | 16,097 |
| 4.2 | Net cash from / (used in) operating activities (item 1.9 above) | (122) | (1,590) |
| 4.3 | Net cash from / (used in) investing activities (item 2.6 above) | - | - |

| Consolidated statement of cash flows | | Current quarter $A'000 | Year to date (6 months) $A'000 |
|---|---|---|---|
| 4.4 | Net cash from / (used in) financing activities (item 3.10 above) | 11 | 218 |
| 4.5 | Effect of movement in exchange rates on cash held | (2) | 41 |
| **4.6** | **Cash and cash equivalents at end of period** | **14,766** | **14,766** |

| 5. | Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts | Current quarter $A'000 | Previous quarter $A'000 |
|---|---|---|---|
| 5.1 | Bank balances | 4,766 | 4,879 |
| 5.2 | Call deposits | 10,000 | 10,000 |
| 5.3 | Bank overdrafts | - | - |
| 5.4 | Other (provide details) | - | - |
| **5.5** | **Cash and cash equivalents at end of quarter (should equal item 4.6 above)** | **14,766** | **14,879** |

| 6. | Payments to related parties of the entity and their associates | Current quarter $A'000 |
|---|---|---|
| 6.1 | Aggregate amount of payments to related parties and their associates included in item 1 | 150 |
| 6.2 | Aggregate amount of payments to related parties and their associates included in item 2 | - |

*Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.*

| 7. | Financing facilities<br>*Note: the term "facility' includes all forms of financing arrangements available to the entity.*<br>*Add notes as necessary for an understanding of the sources of finance available to the entity.* | Total facility amount at quarter end $A'000 | Amount drawn at quarter end $A'000 |
|---|---|---|---|
| 7.1 | Loan facilities | - | - |
| 7.2 | Credit standby arrangements | - | - |
| 7.3 | Other (please specify) | - | - |
| 7.4 | **Total financing facilities** | - | - |

| | | |
|---|---|---|
| 7.5 | **Unused financing facilities available at quarter end** | - |

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

| |
|---|
| |

| 8. | Estimated cash available for future operating activities | $A'000 |
|---|---|---|
| 8.1 | Net cash from / (used in) operating activities (item 1.9) | (122) |
| 8.2 | Cash and cash equivalents at quarter end (item 4.6) | 14,766 |
| 8.3 | Unused finance facilities available at quarter end (item 7.5) | - |
| 8.4 | Total available funding (item 8.2 + item 8.3) | 14,766 |
| 8.5 | **Estimated quarters of funding available (item 8.4 divided by item 8.1)** | **121** |

*Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.*

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

| |
|---|
| |

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

| |
|---|
| |

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

| |
|---|
| |

*Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.*

## Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 31 January 2022

Authorised by: By the Board
(Name of body or officer authorising release – see note 4)

**Notes**

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.